Note 4 - License Agreements (Details) (USD $)	3 Months Ended		6 Months Ended		3 Months Ended				6 Months Ended		12 Months Ended				1 Months Ended				6 Months Ended			12 Months Ended	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended	1 Months Ended		3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended	1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013 Revenue Relating to Signing Fee and Milestone Payment [Member] Meda AB [Member]	Jun. 30, 2012 Revenue Relating to Signing Fee and Milestone Payment [Member] Meda AB [Member]	Jun. 30, 2013 Revenue Relating to Commercial Sales [Member] Meda AB [Member]	Jun. 30, 2012 Revenue Relating to Commercial Sales [Member] Meda AB [Member]	Jun. 30, 2013 Revenue Relating to Commercial Sales [Member] Meda AB [Member]	Jun. 30, 2012 Revenue Relating to Commercial Sales [Member] Meda AB [Member]	Dec. 31, 2012 Portion Payable in 2012 [Member] Current Payable [Member] Epitome/Dalhousie (Member)	Dec. 31, 2012 Upon Achievement of Product Development and Regulatory Approval Milestones [Member] Endo Pharmaceuticals Inc. [Member]	Dec. 31, 2012 Upon Attainment of Sales-based Milestones [Member] Endo Pharmaceuticals Inc. [Member]	Dec. 31, 2012 Epitome/Dalhousie (Member) Current Payable [Member]	Jun. 30, 2012 Reimbursement Revenue (Member) Meda AB [Member]	Jun. 30, 2012 Reimbursement Revenue - Clinical Trials (Member) Meda AB [Member]	Jul. 31, 2013 Current Payable [Member] Epitome/Dalhousie (Member)	Jun. 30, 2012 Meda AB [Member]	Jun. 30, 2013 Meda AB [Member]	Jun. 30, 2012 Meda AB [Member]	May 31, 2010 Meda AB [Member]	Dec. 31, 2012 Epitome/Dalhousie (Member)	Mar. 31, 2008 Myrexis, Inc [Member]	Jun. 30, 2013 Myrexis, Inc [Member]	Jun. 30, 2012 Myrexis, Inc [Member]	Jun. 30, 2013 Myrexis, Inc [Member]	Jun. 30, 2012 Myrexis, Inc [Member]	Dec. 31, 2012 Myrexis, Inc [Member]	Sep. 30, 2008 DURECT [Member]	Dec. 31, 2006 DURECT [Member]	Jun. 30, 2013 DURECT [Member]	Jun. 30, 2012 DURECT [Member]	Jun. 30, 2013 DURECT [Member]	Jun. 30, 2012 DURECT [Member]	Dec. 31, 2003 Endo Pharmaceuticals Inc. [Member]	Jun. 30, 2013 Endo Pharmaceuticals Inc. [Member]	Jun. 30, 2012 Endo Pharmaceuticals Inc. [Member]	Jun. 30, 2013 Endo Pharmaceuticals Inc. [Member]	Jun. 30, 2012 Endo Pharmaceuticals Inc. [Member]	Dec. 31, 2012 Endo Pharmaceuticals Inc. [Member]	Dec. 31, 2006 Shire BioChem (Member)	Jun. 30, 2013 Shire BioChem (Member)	Dec. 31, 2012 Shire BioChem (Member)
Note 4 - License Agreements (Details) [Line Items]
Cash Received for Signing Fee from Agreement																					$ 3,000,000
Cash Received for Milestone Payment																					2,000,000
Proceeds from Sale of Intangible Assets																		2,000,000
Cost of Goods Sold	0	396,000	143,000	396,000														600,000
Licenses Revenue					0	3,900,000	0	600,000	300,000	600,000								2,000,000	300,000	4,100,000				0	15,000	0	31,000				68,000	68,000	136,000	136,000		3,000	10,000	6,000	20,000
Sales Revenue, Goods, Net	0	577,000	283,000	583,000														500,000
Reimbursement Revenue															100,000	100,000
Deferred Revenue, Revenue Recognized		3.8																		3,800,000
License Costs											100,000			300,000			100,000					500,000																			500,000
Proceeds from License Fees Received																							1,000,000						2,250,000	1,000,000					7,500,000
Total Revenue Under License Agreement																												700,000
Effect on Future Cash Flows, Amount												52,500,000	30,000,000																											82,500,000		26,000,000
Debt Instrument, Increase, Accrued Interest																																											$ 200,000